Collin M. Stultz | |
---|---|
Born | May 1967 |
Nationality | American |
Citizenship | United States |
Academic background | |
Education | AB, M.D., Ph.D. |
Alma mater | Harvard University Harvard Medical School Harvard College |
Academic work | |
Institutions | Massachusetts Institute of Technology |
Collin M. Stultz is an American biomolecular engineer,physician-scientist and academic at the Massachusetts Institute of Technology and the Massachusetts General Hospital. He is the Nina T. and Robert H. Rubin Professor in Medical Engineering and Science at MIT,a Professor of Electrical Engineering and Computer Science also at MIT,a faculty member in the Harvard-MIT Division of Health Sciences and Technology,and a cardiologist at the Massachusetts General Hospital. [1] He is also co-Director of the Harvard–MIT Program in Health Sciences and Technology [2]
Stultz's research is focused on understanding the behavior of biomolecules that are involved in common human diseases;on development of machine learning models to identify high risk patients;and on the development of optimal treatment strategies for high risk patients. [3] His work involves the use of computational modeling and machine learning. He is a past recipient of a Burroughs Wellcome Award in the Biomedical Sciences, [4] and a NSF Career Award. [5] He is also a member of the American Institute for Medical and Biological Engineering College of Fellows. [6]
Stultz received his A.B. magna cum laude in Mathematics and Philosophy from Harvard College in 1988. He then went on to receive a M.D. magna cum laude from Harvard Medical School and a Ph.D. in Biophysics from Harvard University,both in 1997. [7] His Ph.D. thesis work was done in the laboratory of Nobelist Martin Karplus. [8]
Stultz joined Harvard Medical School as a Clinical Fellow in 1997,becoming a Research Fellow in 2000. At the same time,he also worked as an Intern,Resident and Cardiology Fellow at the Brigham &Women's Hospital. He then joined MIT in 2003 as a Postdoctoral Fellow and became an Assistant Professor in 2004. [1] He was subsequently,appointed the Keck Associate Professor of Biomedical Engineering in 2007. [9] In 2014,Stultz became Full Professor. Stultz was also appointed to the Committee on Higher Degrees in Biopyshics at Harvard University in 2004 and joined the cardiology staff at the Massachusetts General Hospital in 2017. [10]
In addition to his academic appointments,Stultz is a member of the Research Laboratory of Electronics (RLE), [11] and an associate member of the Computer Science and Artificial Intelligence Laboratory (CSAIL) at MIT. He currently leads the Computational Cardiovascular Research Group at MIT. [12]
Stultz was featured in the 2012 book The Human Face of Big Data,highlighting the software he and co-workers developed,which uses electrocardiographic data to identify patients at high risk for a heart attack. [13]
Shores Salter and Stultz’s efforts to help a Boston Marathon bombing survivor in the immediate aftermath of the attack are described in the 2017 book Perfect Strangers. [14]
Stultz's research is focused on understanding the behavior of biomolecules that are involved in common human diseases;on development of machine learning models to identify high risk patients;and on the development of optimal treatment strategies for high risk patients. His work involves the use of computational modeling and machine learning. [15]
Stultz began his career in computational biophysics,modeling the structure and function of flexible proteins that play a role in a number of common human diseases. His early research focused on building and applying computational tools to improve understanding of disease processes at the molecular level. [16] [17] His work in this area has involved using a combination of both computational/theoretical models coupled with biochemical experiments,which are designed to test and refine these models. Most notably,Stultz’research group has developed methods for analyzing and modeling intrinsically disordered proteins (IDPs) that are involved in neurodegenerative disorders. [18] In the mid 2010s,he and his coworkers developed a novel method for modeling IDPs that uses Bayesian statistics to quantify the uncertainty in the underlying structural ensemble. Stultz and his lab have also developed a variational Bayes’method that enables them to apply these methods to larger systems in a fraction of the CPU time that would be required using a standard Bayes’formalism. [19] [20]
In recent years,work in Stultz’s group has shifted to the application of signal processing and machine learning tools to help identify patients at elevated risk of cardiovascular death after an acute coronary syndrome. Stultz and collaborators have developed several ECG-based metrics that help in identifying patients at elevated risk of cardiovascular death after an acute coronary syndrome. [21] [22]
Stultz has received several honors in recognition of his work. These include a James Tolbert Shipley Prize from Harvard Medical School,a Burroughs Wellcome Fund Career Award (2003),the Irving London Teaching Award (2006), [23] the W. M. Keck Career Development Professorship in Biomedical Engineering from MIT (2007),a Career Award from the National Science Foundation (2008),a Renée Finn Faculty Research Innovation Fellowship (2014). [24] He was inducted into the American Institute for Medical and Biological Engineering College of Fellows. [25] for "ground-breaking contributions to the understanding of protein function in health and disease".
Chest pain is pain or discomfort in the chest,typically the front of the chest. It may be described as sharp,dull,pressure,heaviness or squeezing. Associated symptoms may include pain in the shoulder,arm,upper abdomen,or jaw,along with nausea,sweating,or shortness of breath. It can be divided into heart-related and non-heart-related pain. Pain due to insufficient blood flow to the heart is also called angina pectoris. Those with diabetes or the elderly may have less clear symptoms.
Benoît Roux is an Amgen Professor of Biochemistry and Molecular Biophysics at the University of Chicago. He has previously taught at University of Montreal and Weill Medical College of Cornell University. Benoît Roux was a recipient of the 1998 Rutherford Memorial Medal in Chemistry,awarded by the Royal Society of Canada.
Martin Karplus is an Austrian and American theoretical chemist. He is the Director of the Biophysical Chemistry Laboratory,a joint laboratory between the French National Center for Scientific Research and the University of Strasbourg,France. He is also the Theodore William Richards Professor of Chemistry,emeritus at Harvard University. Karplus received the 2013 Nobel Prize in Chemistry,together with Michael Levitt and Arieh Warshel,for "the development of multiscale models for complex chemical systems".
The drug aprotinin,is a small protein bovine pancreatic trypsin inhibitor (BPTI),or basic trypsin inhibitor of bovine pancreas,which is an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzymes. Under the trade name Trasylol,aprotinin was used as a medication administered by injection to reduce bleeding during complex surgery,such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis,the process that leads to the breakdown of blood clots. The aim in its use was to decrease the need for blood transfusions during surgery,as well as end-organ damage due to hypotension as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death;this was confirmed by follow-up studies. Trasylol sales were suspended in May 2008,except for very restricted research use. In February 2012 the European Medicines Agency (EMA) scientific committee reverted its previous standpoint regarding aprotinin,and has recommended that the suspension be lifted. Nordic became distributor of aprotinin in 2012.
David J. States is an American biophysicist who is Professor of Human Genetics at the University of Michigan. His research group is using computational methods to understand the human genome and how it relates to the human proteome. He is the Director of the Michigan NIH Bioinformatics Training Program and a Senior Scientist in the National Center for Integrative Biomedical Informatics.
David Haussler is an American bioinformatician known for his work leading the team that assembled the first human genome sequence in the race to complete the Human Genome Project and subsequently for comparative genome analysis that deepens understanding the molecular function and evolution of the genome.
Vamsi K. Mootha is an Indian-born American physician–scientist and computational biologist. He is an Investigator of the Howard Hughes Medical Institute,Professor of Systems Biology and Medicine at Harvard Medical School,Investigator in the Department of Molecular Biology at Massachusetts General Hospital. He is also an Institute Member of the Broad Institute.
Emery Neal Brown is an American statistician,computational neuroscientist,and anesthesiologist. He is the Warren M. Zapol Professor of Anesthesia at Harvard Medical School and at Massachusetts General Hospital (MGH),and a practicing anesthesiologist at MGH. At MIT he is the Edward Hood Taplin Professor of Medical Engineering and professor of computational neuroscience,the associate director of the Institute for Medical Engineering and Science,and the Director of the Harvard–MIT Program in Health Sciences and Technology.
Søren Brunak is a Danish biological and physical scientist working in bioinformatics,systems biology,and medical informatics. He is a professor of Disease Systems Biology at the University of Copenhagen and professor of bioinformatics at the Technical University of Denmark. As Research Director at the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen Medical School,he leads a research effort where molecular-level systems biology data are combined with phenotypic data from the healthcare sector,such as electronic patient records,registry information,and biobank questionnaires. A major aim is to understand the network biology basis for time-ordered comorbidities and discriminate between treatment-related disease correlations and other comorbidities in disease trajectories. Søren Brunak also holds a position as a Medical Informatics Officer at Rigshospitalet,the Capital Region of Denmark.
Anders Martin Dale is a prominent neuroscientist and professor of radiology,neurosciences,psychiatry,and cognitive science at the University of California,San Diego (UCSD),and is one of the world's leading developers of sophisticated computational neuroimaging techniques. He is the founding Director of the Center for Multimodal Imaging Genetics (CMIG) at UCSD.
Mark A. Gluck is a professor of neuroscience at Rutgers–Newark in New Jersey,director of the Rutgers Memory Disorders Project,and publisher of the public health newsletter,Memory Loss and the Brain. Working at the interface between neuroscience,psychology,and computer science,he studies the neural bases of learning and memory. He is the co-author of Gateway to Memory:An Introduction to Neural Network Models of the Hippocampus and an undergraduate textbook Learning and Memory:From Brain to Behavior.
Kim Kwang-soo is a South Korean neuroscientist.
Jean-Claude Tardif is the Director of the Research Center at the Montreal Heart Institute and Professor of Medicine at the University of Montreal. He received his medical degree (MD) in 1987 from the University of Montreal and specialized in cardiology and research in Montreal and Boston until 1994. Dr. Tardif holds the Canada Research Chair in personalized medicine and the University of Montreal endowed research chair in atherosclerosis. He is also the Scientific Director of the Montreal Health Innovations Coordinating Center (MHICC).
Daniel Mark Wolpert FRS FMedSci is a British medical doctor,neuroscientist and engineer,who has made important contributions in computational biology. He was Professor of Engineering at the University of Cambridge from 2005,and also became the Royal Society Noreen Murray Research Professorship in Neurobiology from 2013. He is now Professor of Neurobiology at Columbia University.
Sarah Amalia Teichmann is a German scientist who is head of cellular genetics at the Wellcome Sanger Institute and a visiting research group leader at the European Bioinformatics Institute (EMBL-EBI). She serves as director of research in the Cavendish Laboratory,at the University of Cambridge and a senior research fellow at Churchill College,Cambridge.
Jane Clarke is an English biochemist and academic. Since October 2017,she has served as President of Wolfson College,Cambridge. She is also Professor of Molecular Biophysics,a Wellcome Trust Senior Research Fellow in the Department of Chemistry at the University of Cambridge. She was previously a Fellow of Trinity Hall,Cambridge. In 2023,she was elected to the National Academy of Sciences.
Finale Doshi-Velez is a computer scientist and the John L. Loeb Professor of Engineering and Applied Sciences at Harvard University. She works on machine learning,computational statistics and healthcare.
Barry H. Honig is an American biochemist,molecular biophysicist,and computational biophysicist,who develops theoretical methods and computer software for "analyzing the structure and function of biological macromolecules."
Lukasz Kurgan is a Polish-Canadian bioinformatician. He is the Robert J. Mattauch Endowed Professor of Computer Science at the Virginia Commonwealth University,in Richmond,Virginia,U.S.A. He was a professor at the University of Alberta between 2003 and 2015. Kurgan earned his Ph.D. in computer science from the University of Colorado at Boulder in 2003 and his M.Sc. degree in automation and robotics from the AGH University of Science and Technology in 1999.
Peter Karl Sorger is a systems and cancer biologist and Otto Krayer Professor of Systems Pharmacology in the Department of Systems Biology at Harvard Medical School. Sorger is the founding head of the Harvard Program in Therapeutic Science (HiTS),director of its Laboratory of Systems Pharmacology (LSP),and co-director of the Harvard MIT Center for Regulatory Science. He was previously a Professor of Biology and Biological Engineering at the Massachusetts Institute of Technology where he co-founded its program on Computational and Systems Biology (CSBi). Sorger is known for his work in the field of systems biology and for having helped launch the field of computational and systems pharmacology. His research focuses on the molecular origins of cancer and approaches to accelerate the development of new medicines. Sorger teaches Principles and Practice of Drug Development at Massachusetts Institute of Technology and Harvard University.